DSIJ Mindshare

HotChips - DR. REDDYES LABORATORIES

Dr. Reddy’s Laboratories (DRL) is a leading generics manufacturer, and one of the leading branded formulations players in the domestic and the Russian markets. DRL's key strength has been vertical integration, which made it a leading Indian pharma company in the US generics business, clocking USD 430 million sales in FY11 despite intense competition and pricing pressure. It has launched nine products in the US generics market so far in FY12, of which five  have limited competition. These factors, along with US generics sales led by limited competition and niche product opportunities are likely to post robust growth going forward. The branded formulations sales in India and Russia too will maintain progressive growth. The company has enhanced its business focus in domestic formulations to penetrate deep in the rural Indian markets. One can look at the stock from a medium to long-term perspective.

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

IPO Analysis29-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR